Lantheus Holdings, Inc (LNTH)
Nasdaq · Common stock · In Vitro & In Vivo Diagnostic Substances
As of Oct 21, 10:57 AM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow LNTH in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on LNTH and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
LNTH at a glance
Key statistics
$6.56B
Market capitalization
- Previous close
- $100.39
- Open
- $100.43
- Day range
- $100.26 – $100.43
- Volume
- 236.1K
- Average volume (30 sessions)
- 1.04M
- Shares outstanding
- 65.30M
- Price / earnings
- 23.8
- Earnings per share
- $4.22
- Price / book
- 5.0
- Price / sales
- 4.2
- Beta (1 year, vs SPY)
- 0.60
Where the price sits in its year
52-week range
81% of the range
- Below the 52-week high
- -10.3%
- Above the 52-week low
- +100.1%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $99.93+0.5%
- 50-day average
- $100.34+0.0%
- 200-day average
- $90.09+11.4%
Between the conventional 30 and 70 bands.
+0.4%
1 week
+0.1%
1 month
-4.0%
3 months
+50.8%
Year to date
+80.6%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with LNTH
LNTH on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on LNTH.
See the plans →
Every planScreen names like LNTH
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on LNTH
Put LNTH on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on LNTH
See whether there is an open premium alert on LNTH, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
LNTH headlines
- Curium Announces Definitive Agreement to Merge with Lantheus
GlobeNewswire Inc. · Aug 3, 2026
- Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
GlobeNewswire Inc. · Feb 26, 2026
- Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time
GlobeNewswire Inc. · Feb 12, 2026
- Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
GlobeNewswire Inc. · Jan 2, 2026
- Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan
GlobeNewswire Inc. · Sep 24, 2025
SEC Form 4, most recent first
Insider filings
Marshall Robert J. Jr.
−721
CFO and Treasurer · Shares withheld for tax
$72.79K · Aug 31, 2026
Brown Kimberly
−463
Chief Accounting Officer · Shares withheld for tax
$46.72K · Aug 17, 2026
Dinkelborg Ludger
−2.5K
See Remarks · Shares withheld for tax
$255.91K · Aug 17, 2026
Ber Gerard
−381
Director · Shares withheld for tax
$36.83K · May 14, 2026
Heino Mary Anne
−1.2K
Executive Chair and CEO, Director · Shares withheld for tax
$118.61K · May 14, 2026
Baylor-Henry Minnie
+4.1K
Director · Grant or award
· May 14, 2026
EASTLAND JULIA MARIE
+4.1K
Director · Grant or award
· May 14, 2026
LENO SAM R
+4.1K
Director · Grant or award
· May 14, 2026
About Lantheus Holdings, Inc
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- North Billerica, MA
- Employees
- 1,193
- Listed since
- Jun 25, 2015
- Website
- lantheus.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.